Skip to content
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Pediatric Rheumatology

Building Your Care Team: Specialists and Preparation

At a Glance

Children with disabling pansclerotic morphea need coordinated care from pediatric rheumatology and dermatology, often with therapy, wound, nutrition, orthopedic, pain, and mental health support. Bring imaging, biopsy materials, photos, and a timeline to the first visit.

Because disabling pansclerotic morphea of childhood (DPMC) is exceptionally rare and aggressive, managing it requires a multidisciplinary care team—a group of specialists from different fields who work together to treat the “whole child” [1][2]. Prompt consultation or co-management with a specialized center where rheumatologists and dermatologists collaborate is recommended, while your primary pediatrician remains vital for vaccines, routine illness, and coordination [3][1].

The Core Specialists (Your “Must-Have” Roster)

The leadership of your child’s team should be a partnership between two key fields:

  • Pediatric Rheumatology: They frequently co-lead the team and manage the systemic medications (like methotrexate or steroids) needed to calm the immune system [1][4].
  • Pediatric Dermatology: They focus on the skin’s surface, monitoring disease activity and distinguishing DPMC from other rare skin conditions [1][5].

Supporting these leaders, your child will also need:

  • Pediatric Physical and Occupational Therapy: Essential for preserving movement and preventing permanent joint tightening (contractures) [6][7].
  • Wound Care Specialists: Experts in managing deep, chronic ulcers and preventing serious infections like sepsis [8][2].
  • Pediatric Dietitian: Critical for monitoring your child’s growth and preventing cachexia (severe weight loss) caused by the high energy demands of the disease [8][9].
  • Pediatric Orthopedics: Needed if the hardening affects bone growth or if surgery is required to balance limb lengths or release a fused joint [6][7].
  • Pediatric Pain Management and Palliative Care: To assist with symptom relief and improve daily comfort.
  • Pediatric Psychology: To help your child and family cope with the significant emotional and social impact of a chronic, visible disease [6][10].

Vetting Your Team: Questions to Ask

Not every children’s hospital has deep experience with DPMC. When you meet a new team, it is important to understand their level of expertise:

  1. Experience: “How many children with deep, generalized, or pansclerotic morphea have you treated?” [3].
  2. Collaboration: “Do the rheumatologists and dermatologists here have a combined clinic, or a formal way to review cases together?” [1].
  3. Specialized Review: “Do you have a dermatopathologist (a skin-biopsy expert) who is specifically familiar with the deep tissue layers involved in DPMC?” [5].
  4. Advanced Imaging: “Do you have experience using MRI or thermography to monitor the depth of inflammation in children?” [11][12].
  5. Coordination: Ask about options for telehealth visits for routine check-ins, and how the center will establish a named coordinator and an explicit plan for medication reconciliation and after-hours communication with your local team.

Preparing for the First Appointment

For a rare disease, the first visit is often dense with information. You can help your team by bringing “physical artifacts”—actual evidence of the disease’s history [13][14].

What to Bring

  • Imaging: Ensure actual CD/DVDs of MRIs or ultrasounds (DICOM files) are transferred directly between institutions where possible; the paper report alone is not enough [11].
  • Pathology Slides/Blocks: If a biopsy was already done elsewhere, request the glass slides and tissue blocks from that hospital to bring for a “second look” by your new team [5].
  • Dated Photographs: Pictures of the skin from weeks or months ago are vital. They help the team see exactly how fast the disease is moving [14].
  • Full Medical Timeline: Write down exactly when symptoms started, which areas were affected first, any history of fevers or infections, and a list of all past medications and their side effects [13][15].
  • Growth and Movement Logs: Any notes on recent weight loss or specific movements (like reaching up or walking) that have become harder for your child [16][8].

Having this information ready allows the specialists to spend less time digging for data and more time discussing the aggressive treatment plan your child needs [1].

Common questions in this guide

Which specialists should be involved in caring for a child with DPMC?
A pediatric rheumatologist and pediatric dermatologist often co-lead care, ideally at a center experienced with severe childhood morphea. Physical and occupational therapists, wound specialists, a dietitian, orthopedics, pain or palliative care, and a psychologist may join the team based on the child’s needs.
How can I tell whether a hospital has experience treating DPMC?
Ask how many children with deep, generalized, or pansclerotic morphea the team has treated. You can also ask whether rheumatology and dermatology review cases together, whether a skin-biopsy specialist is available, and whether the center uses MRI or heat-based imaging to monitor deeper inflammation.
What should I bring to my child’s first DPMC appointment?
Bring the original imaging files, such as MRI or ultrasound files, rather than only written reports. If a biopsy was performed, ask for the glass slides and tissue blocks, and bring dated skin photographs, a timeline of symptoms, medication and side-effect records, and notes about growth and movement.
Why might my child need MRI or thermography for DPMC?
These tests can help the team assess how deep inflammation extends and monitor changes over time. MRI provides images of deeper tissues, while thermography uses skin-temperature patterns as additional information about activity. The specialists will decide which tests are useful for your child.
How can the care team help prevent DPMC complications?
Physical and occupational therapy can help preserve movement and reduce permanent joint tightening. Wound care can help manage ulcers and lower infection risk, while nutrition support, medication treatment, pain care, and regular monitoring address other effects of the disease.
How should a specialty center coordinate with our local pediatrician?
Ask whether the center will name a coordinator, share a written care plan, and reconcile medicines with the local pediatrician. It is also helpful to clarify who handles routine illnesses and vaccines, how records are transferred securely, and whom to contact after hours.

Get notified when new evidence is published on disabling pansclerotic morphea of childhood.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (16)
  1. 1

    Development of minimum standards of care for juvenile localized scleroderma.

    Constantin T, Foeldvari I, Pain CE, et al.

    European journal of pediatrics 2018; (177(7)):961-977 doi:10.1007/s00431-018-3144-8.

    PMID: 29728839
  2. 2

    Disabling pansclerotic morphoea: a century of discovery.

    Hua VK, Chang J, Laxer RM, Broderick L

    The British journal of dermatology 2025; (192(4)):585-596 doi:10.1093/bjd/ljae443.

    PMID: 39520387
  3. 3

    Juvenile localized scleroderma: a large retrospective cohort study from a tertiary care center.

    Egeli BH, Dallas J, Reusch DB, et al.

    Pediatric rheumatology online journal 2025; (23(1)):63 doi:10.1186/s12969-025-01116-0.

    PMID: 40481578
  4. 4

    Systemic therapy in juvenile localized scleroderma.

    Foeldvari I, Marrani E

    Expert review of clinical immunology 2023; (19(10)):1225-1238 doi:10.1080/1744666X.2023.2237685.

    PMID: 37462119
  5. 5

    Connective tissue nevus misdiagnosed as juvenile localized scleroderma.

    Tirelli F, Giraudo C, Soliani M, et al.

    Pediatric rheumatology online journal 2023; (21(1)):125 doi:10.1186/s12969-023-00913-9.

    PMID: 37848914
  6. 6

    Update on Management of Morphea (Localized Scleroderma) in Children.

    George R, George A, Kumar TS

    Indian dermatology online journal 2020; (11(2)):135-145 doi:10.4103/idoj.IDOJ_284_19.

    PMID: 32477969
  7. 7

    Orthopedic complications of linear morphea: Implications for early interdisciplinary care.

    Schoch JJ, Schoch BS, Werthel JD, et al.

    Pediatric dermatology 2018; (35(1)):43-46 doi:10.1111/pde.13336.

    PMID: 29119592
  8. 8

    Challenges in the diagnosis and treatment of disabling pansclerotic morphea of childhood: case-based review.

    Soh HJ, Samuel C, Heaton V, et al.

    Rheumatology international 2019; (39(5)):933-941 doi:10.1007/s00296-019-04269-w.

    PMID: 30838436
  9. 9

    [Clinical Nutrition for the Medical Patient: From Screening to Diagnosis and Start of Nutritional Therapy].

    Eilinger L, Arifi T, Dziadova V, Schuetz P

    Praxis 2022; (111(7)):367-373 doi:10.1024/1661-8157/a003862.

    PMID: 35611485
  10. 10

    Predictors of family impact of juvenile localized scleroderma.

    Milovanova K, Adly M, Lethebe BC, et al.

    Pediatric dermatology 2021; (38(5)):1137-1142 doi:10.1111/pde.14683.

    PMID: 34263473
  11. 11

    Pediatric morphea: MRI evaluation of superficial and deep tissue involvement and impact in clinical practice.

    Reyes Recasens MP, Pope EI, Sibbald C, et al.

    Pediatric radiology 2026; (56(7)):1547-1560 doi:10.1007/s00247-026-06647-6.

    PMID: 42176060
  12. 12

    Role of imaging in morphea assessment: A review of the literature.

    Khorasanizadeh F, Kalantari Y, Etesami I

    Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) 2023; (29(7)):e13410 doi:10.1111/srt.13410.

    PMID: 37522502
  13. 13

    Extracutaneous involvement is common and associated with prolonged disease activity and greater impact in juvenile localized scleroderma.

    Li SC, Higgins GC, Chen M, et al.

    Rheumatology (Oxford, England) 2021; (60(12)):5724-5733 doi:10.1093/rheumatology/keab238.

    PMID: 33711155
  14. 14

    Comparative study between fractional CO2 laser (10,600 nm) and microneedling in treatment of morphea: dermoscopic and histopathological evaluation.

    El-Shahawy MM, Farag AS, El-Khalawany MA, Pessar DAH

    Archives of dermatological research 2025; (317(1)):276 doi:10.1007/s00403-024-03674-x.

    PMID: 39825977
  15. 15

    Mycophenolate mofetil for methotrexate-resistant juvenile localized scleroderma.

    Martini G, Saggioro L, Culpo R, et al.

    Rheumatology (Oxford, England) 2021; (60(3)):1387-1391 doi:10.1093/rheumatology/keaa392.

    PMID: 32978631
  16. 16

    Capturing the Range of Disease Involvement in Localized Scleroderma: The Localized Scleroderma Total Severity Scale.

    Li SC, Rabinovich CE, Becker ML, et al.

    Arthritis care & research 2024; (76(5)):616-626 doi:10.1002/acr.25281.

    PMID: 38148547

This page is for educational purposes only and does not constitute medical advice. Your child’s pediatric rheumatology and dermatology team should guide diagnosis, treatment, and specialist coordination.